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598Secondary Lymphoid Organs Contribute to, but Are
Not Required for the Induction of Graft-versus-Host
Responses following Allogeneic Bone Marrow
Transplantation: A shifting Paradigm for T Cell
Allo-activation
Ines A. Silva,1 Krystyna Olkiewicz,1 David Askew,2 Jacquelyn M. Fisher,1
Meghana N. Chaudhary,1 Kevin M. Vannella,1 Daphne T. Deurloo,1 Sung W. Choi,1
Elizabeth M. Pierce,2 Shawn G. Clouthier,2 Chen Liu,3 Kenneth R. Cooke1,2Graft-versus-host disease (GVHD) remains the major complication of allogeneic bone marrow transplanta-
tion (allo-BMT). GVHD fundamentally depends upon the activation of donor T cells by host antigen-
presenting cells (APCs), but the precise location of these interactions remains uncertain. We examined
the role of secondary lymphoid organs (SLO) in the induction of GVHD by using homozygous aly/aly mice
that are deficient in lymph nodes (LNs) and Peyer’s patches (PPs). Lethally irradiated, splenectomized, aly/
aly (LN/PP/Sp2/2) mice and sham-splenectomized, aly/1 (LN/PP/Sp1/1) mice received BMT from either
syngeneic (aly/aly) or allogeneic, major histocompatibility complex (MHC) disparate donors. Surprisingly, al-
though LN/PP/Sp2/2 allo-BMT recipients experience a survival advantage, they developed significant sys-
temic and target organ GVHD that is comparable to LN/PP/Sp1/1 controls. Early after allo-BMT, the
activation and proliferation of donor T cells was significantly greater in the BM cavity of LN/PP/Sp2/2
mice compared to LN/PP/Sp1/1 controls. Donor T cells in LN/PP/Sp2/2 mice demonstrated cytolytic ac-
tivity in vitro, but Graft vs Leukemia (GVL) activity could be overcome by increasing the tumor burden. These
data suggest that SLO contribute to, but are not required for, allogeneic T cell responses, and suggest that the
BM may represent an alternative, albeit less efficient site for T cell activation following allo-BMT.
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Immunologic dysregulation occurring after allo-
BMT represents a double-edged sword to the clinical
BMT specialist. On one hand, T cells and cytokines
responsible for the toxicity of graft-versus-host disease
(GVHD) limit the use of this form of therapy, but on
the other, they enhance the therapeutic potential of
BMT through the graft-versus-leukemia (GVL) effect.
Unfortunately, beneficial GVL effects are closely
linked to the deleterious consequences of GVHD.
GVHD is the most significant contributor to nonre-
lapse mortality after allo-BMT, and remains the pri-
mary barrier to broadening the scope of this
treatment option; outcomes have not improved over
the past 2 decades despite our enhanced knowledge
of the biology of GVHD.
Although interactions between donor T cells and
antigen-presenting cells (APCs) are fundamental to
the development of both GVHD and GVL, the exact
location of these encounters remains speculative.
The prevailing theory is that secondary lymphoid
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nor T cells following allo-BMT, but published data on
this topic are conflicting. Previous work showed that
Peyer’s patches (PPs) are critical for the generation
of donor-derived, anti-host cytotoxic T lymphocytes
(CTLs) that cause acute GVHD (aGVHD) after non-
myeloblative (NMA) conditioning [1]. Moreover,
tracking of cell migration early after BMT, using bio-
luminescent imaging, revealed increased numbers of T
cells in a variety of secondary lymphoid tissues includ-
ing the spleen, PP and mesenteric lymph nodes (LNs)
[2]. By contrast, a recent study demonstrated that PPs
are not required for aGVHD after myeloablative (MA)
conditioning [3].
We set out to examine the role of SLO in GVHD
induction and hypothesized that if SLO, including
LN, PP, and spleen, are essential for donor T cell ac-
tivation, then the absence of these tissues in the BMT
recipients should completely abrogate GVHD. We
designed experiments using unique mutant mice
(alymphoplasia; aly/aly) as BMT recipients in well-
described major histocompability complex (MHC)-
disparate BMT systems. Aly/aly mice were originally
described following a spontaneous autosomal muta-
tion in the gene encoding NF-kB-inducing kinase
[4]. This mutation results in a systemic absence of
LN, PP [4-6], and recently discovered isolated
lymphoid follicles (ILF) [7,8], as well as structural
defects of the spleen and thymus. The aly mutation is
also associated with reduced levels of serum IgG and
complete absence of IgA, the latter serving as an
effective marker to phenotypically distinguish
between homozygous and heterozygous littermates
[5,6,9,10]. Although deficiencies in cell-mediated im-
mune function, such as impaired intestinal humoral
immune responses, are observed in aly/aly mice, nor-
mal dendritic cell (DC) function is preserved [5].
Thus, we reasoned that following splenectomy, aly/
aly mice would lack all traditional SLO (LN/PP/
Sp2/2), and therefore serve as suitable BMT recipi-
ents to test our central hypothesis.
We found that LN/PP/Sp2/2 recipients devel-
oped clinical and target organ GVHD that was com-
parable, if not greater than, both LN/PP/Sp1/1
littermate and wild-type, C57BL/6 controls. Nearly
identical results were also found in a second and
more robust strain combination wherein MHC-
disparate B10.BR (H-2k) mice were used as allogeneic
BMT donors. Although present, the severity of
GVHD was less severe and the generation of GVL
responses could be overcome when tumor burden
was increased. Collectively, our data challenge the
paradigm that secondary lymphoid tissues are
required for GVHD induction, but suggest they
may be required for the generation of optimal GVL
responses.MATERIALS AND METHODS
Mice and BMT
Female C57BL/6 (H-2b) and male and female
BALB/c (H-2d), and B10.BR (H-2k) mice were
purchased from the JacksonLaboratory (JAX; BarHar-
bor,ME).Homozygous aly/aly and heterozygous aly/1
(H-2b) mice were originally purchased from Japan and
bred at the University of Michigan [4]. C57BL/6 mice
deficient in alpha(1,3)-fucosyltransferase VII and
alpha(2,3)-sialyltransferase IV (FucT dko) were kindly
provided by Dr. John Lowe. Synthesis of fucosylated
glycans required for E-, P-, and L-selectin ligand activ-
ity is catalyzed by an ordered series of reactions that are
ultimately controlled by specific a(1,3) fucosyltrans-
ferases, including Fuc-TIV and Fuc-TVII [11,12].
FucT dko mice lack P- and E-selectin ligands on
leukocyte surfaces and L-selectin ligands on high
endothelial venules of SLO where it is constitutively
expressed. Thus, lymphocyte homing to LNs is
completely abrogated in FucT dko mice, whereas
migration to PP is reduced by approximately 50% [13].
Mice received BMT according to a standard proto-
col [14]. Briefly, lethally irradiated (13 Gy; 137Cs
source), splenectomized aly/aly (LN/PP/Sp2/2) or
sham-splenectomized aly/1 littermates (LN/PP/
Sp1/1) received 5  106 BM cells supplemented
with 2.0 or 5.0 106 AutoMacs (Miltenyi Biotech, Au-
burn, CA) purified splenic T cells (CD90-conjugated
magnetic beads; Miltenyi Biotech) from syngeneic
(aly/aly) or allogeneic BALB/c (H-2d), or B10.BR
(H-2k) donors. T cell (TCRab1) purity was routinely
between 80% and 90%. In some experiments, wild-
type C57BL/6 or C57BL/6 FucT dko recipients of
syngeneic (C57BL/6) or allogeneic (Balb/c or
B10.BR) BMT served as additional controls. Donor
and recipient mice were between 8 to 20 weeks of
age at the time of use. Mice were housed in microiso-
lator cages and received normal chow and autoclaved
hyperchlorinated drinking water for the first 3 weeks
after BMT, and filtered water thereafter. All proce-
dures were approved by and conducted in accordance
with regulations of the University of Michigan Com-
mittee on the Use and Care of Animals, and the Case
Western Reserve University Institutional Animal
Care and Use Committee.Splenectomy and Sham Procedure
Splenectomies were performed under anesthesia in
a Unit for Laboratory Animal Medicine (ULAM) des-
ignated surgical room at the University of Michigan.
Briefly, mice received the inhaled anesthetic AErrane
(isoflurane, USP, Baxter, IL) using a device that con-
trols the amount of isoflurane and O2 released inside
a restraining container. Once adequately anesthetized,
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mostat and an electrocautery tool. The peritoneal cav-
ity and skin were closed with surgical staples. Mice
were observed until they fully recovered from anesthe-
sia. Heterozygous aly/1 littermates underwent a sham
procedure wherein the spleen was lifted and gently
placed back in the peritoneal cavity before applying
surgical staples. Greater than 90% of the animals sur-
vived each procedure and were ultimately able to
undergo BMT after a recovery period of 2 weeks.
Evaluation of GVHD Severity
Survival was monitored daily and GVHD clinical
scores were assessed weekly for all BMT recipient
mice using a previously described system [15]. Acute
GVHDwas also assessed in the small (ileum) and large
(ascending) intestine, liver, and skin. Tissues were har-
vested from animals at defined time points after BMT
and prepared for histologic examination. Slides were
coded without reference to mouse type or prior treat-
ment status and examined by a single pathologist
(C.L.) using semiquantitative scoring systems previ-
ously described. Seven parameters known to be consis-
tent with GVHD were scored for small bowel and
large bowel, and 10 parameters were evaluated for
liver. Skin GVHD was evaluated by using sections of
tongue as described [16].
Mixed Lymphocyte Reactions (MLR) and
Cytotoxic T Lymphocyte (CTL) Activity
Ninety-six-well plates (Sarstedt, NC) were seeded
with 2.0  106 AutoMACS purified (CD90 mAbs)
BALB/c or B10.BR T cells in 10% fetal calf serum
(FCS) DMEM and cocultured for 72 hours with 2 
104 BM-derived DCs (see below) or AutoMACS puri-
fied (CD11c1) splenic DCs from either aly/aly, aly/1,
C57BL/6, or FucT dko mice [17]. At 48 hours, 100 mL
of supernatant were collected for cytokine analysis.
Cell cultures were subsequently pulsed with 50 mL of
3H-thymidine (1 mCi/well [0.037 MBq]) and prolifer-
ation was determined 12-20 hours later on a 1205
Betaplate reader (Wallac, Turku, Filand).
For CTL assays, allogeneic (B10.BR or Balb/c) T
cells were cultured for 5 days in a bulk-MLR with
irradiated (2000 rad) whole splenocytes from aly/aly,
aly/1, and C57BL/6 mice. Cells were harvested,
washed, resuspended in warm DMEM medium, and
then slowly transferred to the wall of 15 mL tubes
with 3 mL of Ficoll-Paque Plus (Amersham Biosci-
ence, Piscataway, NJ). Following centrifugation, leu-
kocytes were isolated, washed twice, incubated with
antibodies to CD4 (PE) and CD8 (FITC) (BD Biosci-
ence, San Jose, CA), and analyzed by flow cytometry.
CTL activity was analyzed by 51Cr release assays as de-
scribed previously [18,19]. First, 2  106 allogeneic
EL4 or MBL-2 (H-2b) and syngeneic P815 (H2d)tumor targets were labeled with 10 mL of 100 mCi
(3.7 MBq) of 51Cr sodium salt (NEN Life Sciences
Products, Frederick, CO) after incubation at 37C
for 1.5 hours. Labeled targets were resuspended in
10% FCS RPMI and plated at 104 cells per well in
U-bottom plates (Corning-Costar, Cambridge, MA).
Activated CD81 cells collected following bulk MLR
and normalized by flow cytometry were added to qua-
druplicate wells at varying effector (CD81)-to-target
ratios (starting at 50:1 trough 1.5:1) and incubated at
37C for 4 hours. Maximal and background release
were determined by the addition of Triton-X (Sigma
Chemical, St. Louis, MO) or media alone to targets,
respectively. 51Cr activity in supernatants taken at
hour 4 was determined in a top count liquid microplate
scintillation Counter (Perkin-Elmer, Shelton, CT),
and lysis was expressed as a percentage of maximum.
In some experiments, donor-derived B10.BR T cells
that were collected from the BM cavity of LN/PP/
Sp2/2 BMT recipients served as the effector cell
source in CTL experiments using the JAM assay as de-
scribed [20].Flow Cytometric Analysis
Single-cell suspensions collected from the liver and
bone marrow (BM) on day 3 and 7 after BMT were
counted and subsequently stained with allophycocya-
nin (APC)-conjugated monoclonal antibodies (mAbs)
to CD3 and phycoerythrin (PE)-conjugated mAbs to
either H-2kd, H-2kk, or CD69 (BD Bioscience, Phar-
mingen, San Diego, CA). Two-color flow cytometric
analysis of 1  104 cells was performed using a FACS-
Calibur (BDBiosciences, San Jose,CA). In some exper-
iments, intracytoplasmic cytokine production was
measured in donor-derived B10.BR T cells collected
from the BM cavity of LN/PP/Sp2/2BMT recipients
between days 3 and 5. Following cell surface staining
for CD4 and CD8, cells were fixed, permeabilized,
stained with PE-conjugated mAbs for TNFa, and
IFNg (eBioscience, San Diego, CA), and ultimately
analyzed by 3-color flow cytometric analysis as above.Donor T Cell Divisions In Vivo
In carboxyfluorescein diacetate, succinimidyl ester
(CFDA SE) studies, donor T cells were stained with
Vibrant CFDA SE (Invitrogen, Carlsbad, CA) prior
to injection into recipient mice. CFDA SE was recon-
stituted with dimethyl sulfoxide (DMSO) to a final
concentration of 5 mM. Cells were resuspended in
phosphate-buffered saline (PBS) 1 5% FCS (Gibco,
Gaithersburg, MD) at 10  106/mL and were incu-
bated with CFDA SE for 5 minutes at room tempera-
ture. Incubation was stopped by placing cells on ice for
5 minutes, and cells were washed twice in ice-cold 5%
FCS-RPMI and resuspended in medium with final
Biol Blood Marrow Transplant 16:598-611, 2010 601Secondary Lymphoid Organs and GVHDconcentration 5  106 cells/mL prior to injection into
irradiated BMT recipients.
Cytokine Enzyme-Linked Immunosorbent
Assay (ELISA)
We have established an ELISA protocol to pheno-
type as homozygous (aly/aly) and heterozygous (aly/1)
by screening the sera obtained from 6- to 7-week-old
mice for the absence of IgA (homozygous) or the pres-
ence of IgA (heterozygous) (data not shown). Anti-
bodies used were purchased from R&D Systems
(Minneapolis, MN) and assays were performed
according to the manufacturer’s protocol. Rat anti-
mouse capture and detection mAbs were diluted
1:100 and 1:20,000 (respectively) in Coating Buffer
(Sigma), whereas serum samples were diluted 1:100.
IFNg ELISAs were performed according to the man-
ufacturer’s protocol (OptEIA, BD Biosciences Phar-
mingen, San Diego, CA) and assay sensitivity was
\7.5 pg/mL. Plates were ultimately read at 450 nm
using a microplate reader (Bio-Rad Laboratories, Her-
cules, CA). Samples and standards were duplicated.
Real-Time Quantitative RT-PCR Analysis
T cells were obtained from whole BM collected
between 3 and 5 days after transplantation using
Ficoll-Paque separation. mRNA was extracted from
whole T cells using TRIzol following the manufac-
turer’s protocol (Invitrogen), quantified by specro-
photometry, and stored at 280C. TNFa, IFNg,
perforin, and GAPDH (an internal control) expression
were analyzed by real-time RT-PCR procedure using
an ABI 7300 Real-time PCR system (Applied Biosys-
tems, Foster City, CA). All primers and probes used
were purchased from Applied Biosystems. Target
gene expression was normalized to GAPDH before
the fold change in expression was calculated by com-
paring values obtained from individual allo-SCT
recipients to the average values measured in syngeneic
controls.
Leukemia Induction
GVL activity was assessed using a MBL-2 leuke-
mia model as previously described [21,22]. MBL-2 is
a Moloney virus-induced T cell lymphoma of
C57BL/6 origin (H-2b) and is syngeneic to aly/aly,
aly/1 littermates, and C57BL/6 hosts and allogeneic
to B10.BR (H-2k) donors. On day 0, 1000, 2000, or
5000 BML-2 cells were injected i.v. into subsets of
BMT recipients along with syngeneic (aly/aly) or allo-
geneic (B10.BR) BM and splenic T cells. Survival was
monitored daily and the cause of each death after BMT
was determined by postmortem examination. Death
from MBL-2 was attributable to tumor expansion as
measured by enlargement of the liver and spleen with
macroscopic tumor nodules evident upon necropsyor evidence of hind leg paralysis prior to sacrifice. By
contrast, GVHD death was indicated with the absence
of tumor and the presence of clinical and target organ
GVHD.
In Vivo Treatment with Anti-MadCAM-1
In experiments using C57BL/6 wild-type and
FucT dko mice as BMT recipients, we used the mAb
anti-MadCAM-1 (mucosal addressin cell adhesion
molecule; eBioscience) to block trafficking of T cells
to PPs [23,24]. C57BL/6 wild-type and FucT dko
mice were treated with 2 mg/kg of anti-MadCAM
given intraperitoneally on days 21, 0, 1, 3, 5, 7, and
10 [24-27]. Mice in control groups received
injections of control hamster immunoglobulin.
Statistical Considerations
All values are expressed as the mean6 standard er-
ror margin (SEM). Statistical comparisons between
groups were completed using the parametric, indepen-
dent sample, T test, or the nonparametric Mann-
Whitney test when sample numbers are 5 or less.
Survival curves were generated using Kaplain-Meier
estimates and the Wilcoxon rank-test was used for
analyzing survival data.RESULTS
Characterization of aly/aly Mice Prior to BMT
Homozygous aly/aly and heterozygous aly/1
(H-2b) mice were bred at the University of Michigan;
progeny were distinguished phenotypically by measur-
ing serum IgA levels as described in the Materials and
Methods section (data not shown). Prior to BMT stud-
ies, surrogate, age-matched, littermates were exam-
ined for the presence or absence of LNs and PPs.
Consistent with the previously reported phenotype,
gross and microscopic inspection of aly/aly mice dem-
onstrated the absence of PPs (Figure 1A) and lymph
nodes in traditional anatomic sites (not shown)
[4-6,8,9]. As expected, these structures were present
in both wild-type C57BL/6 mice and heterozygous
(aly/1) littermates (Figure 1A). We next determined
the ability of host aly/aly and aly/1 splenic DCs to
stimulate donor Balb/c T cells in vitro. These studies
were deemed essential prior to completing and inter-
preting BMT experiments to ensure that differences
in the ability of aly/aly APCs to stimulate donor type
T cells would not account for any observed differences
in GVH or GVL responses that could be otherwise
attributed to the lack of SLOs alone. As shown in
Figure 1B-D, no differences in proliferation, IFNg
production, or CTL generation were noted between
groups. Similar results were obtained when either peri-
toneal cells or BM-derived DCs from aly/aly and aly/1
Figure 1. Aly/alymice lack Peyer’s patches, but the allo-stimulatory capacity of their DCs is comparable to littermate controls. The small intestines from
age-matched naı¨ve wild-type C57BL/6, aly/1, and aly/aly mice were harvested, examined, and photographed using a Nikon digital camera alone or at-
tached to a microscope using 10magnification lens. Although readily apparent in both wild-type C57BL/6 and aly/1 heterozygote littermate controls,
aly/alymice lacked visible Peyer’s patches. (A) Splenic DCs were purified from wild-type C57BL/6, aly/1 littermate controls, and aly/alymice and used to
stimulate purified, MHC disparate Balb/c T cells in an MLR as described in the Materials and Methods section. No differences in the ability to stimulate T
cell proliferation (B) IFNg production (C) or the generation of CTL effectors (D) were observed among groups. Data are expressed as mean6 SEM and
are representative of 1 of 3 comparable experiments. Wild-type C57BL/6 aly/1 aly/aly compared to T cells only .
602 Biol Blood Marrow Transplant 16:598-611, 2010I. A. Silva et al.littermates were used as allogeneic stimulator cells and
when purified, MHC disparate B10.BR T cells were
used as responders (data not shown).MICE LACKING SECONDARY LYMPHOID
STRUCTURES DEVELOP aGVHD
In our next set of experiments, lethally irradiated,
splenectomized aly/aly mice (LN/PP/Sp2/2) and
sham-splenectomized, aly/1 mice (LN/PP/Sp1/1)received BMT fromeither syngeneic (aly/aly) or alloge-
neic, MHC-disparate (Balb/c) donors and were subse-
quently followed for signs of GVHD. In some
experiments, wild-type C57BL/6 BMT recipients
were also included as additional allogeneic controls.
As expected, all syngeneic BMT recipients survived
and ultimately were indistinguishable from naı¨ve, un-
transplanted animals. By contrast, LN/PP/Sp1/1
mice receiving allo-BMT developed significant
GVHD with approximately 30% mortality by day 49.
Biol Blood Marrow Transplant 16:598-611, 2010 603Secondary Lymphoid Organs and GVHDAll LN/PP/Sp2/2 allo-BMT recipients also survived,
but surprisingly, they too developed significant
clinical GVHD compared to syngeneic controls
(Figure 2A,B). Histopathologic analysis demonstrated
that enhanced GVHD clinical scores correlated with
significantly greater GVHD target tissue damage in
the liver, intestinal tract, and skin compared to synge-
neic controls at day 49 (Figure 2C-E).When compared
to allogeneic, LN/PP/Sp1/1 littermates, LN/PP/
Sp2/2 allo-BMT recipients developed significantly
greater hepatic GVHD (30.8 6 1.9 versus 20.7 6 2.2;
P\ .01), whereas intestinal GVHD was less severe.
We also examined organs of age-matched naı¨ve aly/aly
mice, and these data in combination with those
obtained from syngeneic controls confirm that pathol-
ogy seen after allo-BMT is secondary to GVHD
(Figure 2C-E). As shown in Figure 3, similar findings
were observed using a second, MHC-disparate mouse
model where in B10.BR mice were used as allo-BMT
donors and GVHD severity is more robust [28,29].0
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leukocyte migration to all SLO, subsets of FucT dko
mice were splenectomized and ultimately treated
with mAbs to MAdCAM-1 at indicated time points.
Wild-type C57BL/6 and FucT dko mice undergoing
sham surgery and treatment with isotype Ig antibodies
served as allogeneic controls. As shown in Table 1,
sham splenectomized, FucT dko syngeneic controls
all survived after BMT, whereas 90% to 100% of allo-
geneic control mice died by day 30. Splenectomized
FucT dko mice treated with anti-MAdCAM-1 anti-
bodies experienced a significant survival advantage,
but they still demonstrated evidence of clinical and tar-
get tissue GVHD. These finding are consistent with
results using aly/aly mice as allo-BMT recipients and
demonstrate that our observations are independent
of strain specificity.Donor T cell expansion in the Liver and BM
Cavity of LN/PP/Sp2/2 Mice 7 Days after
Allo-BMT
To begin to ascertain what extra-lymphoid host
tissues might serve as initial sites for allo-antigenTable 1. Survival and GVHD after allo-BMTusing FucT dko recipie
Recipients SLO status D
syn: FucT dko sham + Ig LN- / Sp+ / PP+
allo: wild-type B6 LN+ / Sp+/ PP+
allo: FucT dko + sham + Ig LN- / Sp+/ PP+
allo: FucT dko + surg+ Ig LN- / Sp- / PP+
allo: FucT dko + surg + anti-Mad LN- / Sp- / PP-
BMT indicates bone marrow transplantation; GVHD, graft-versus-host disease
Lethally irradiated, splenectomized, FucT dko (LN/Sp2/2), sham-splenectomiz
5 106 BM cells and 2.0 106 splenic T cells from allogeneic B10.BR donors.
negative controls. To neutralize migration of naı¨ve T cells to PPs following B
MadCAM-1 antibodies (whereas control animals received control hamster im
Methods section. BMTrecipients were analyzed daily for survival andweekly thr
tissue collected at the time of death, or at the end of the evaluation period was
independent experiments (n 5 9-15 per group). *P < .05 compared with syngexposure, we next examined donor T cell expansion
in the liver and BM cavity 7 days after BMT. As shown
in Table 2, LN/PP/Sp2/2 allo-BMT recipients had
significantly higher numbers of donor, CD31 T cells
in the liver and BM compared to both LN/PP/Sp1/
1 littermate and wild-type C57BL/6 allogeneic
groups and syngeneic controls. As shown in Figure 4,
enhanced trafficking of donor T cells to the liver cor-
related with a significant increase in hepatic GVHD at
day 7 in LN/PP/Sp2/2 mice compared to syngeneic
and both LN/PP/Sp1/1 allogeneic controls (16.0 6
2.2 versus 7.3 6 0.9; P\ .01).Donor T Cells Are Activated and Proliferate in
the BM Cavity of Mice Lacking Secondary
Lymphoid Organs Early after allo-BMT
The elevated numbers of allogeneic donor T cells
in the BM cavity and liver observed on day 7 was in-
triguing, and suggested that either of these 2 organs
might serve as an alternative site for T cell activation
early after allo-BMT. We therefore examined donor
T cell expansion (CD31), activation (CD691), and
proliferation (CFDA-SE) in both anatomic sites 3nts
ay 28 survival
day 28
Clinical Score Intestinal GVHD
100 % 1.5 ± 0 4.6 ± 0.2
0 % NA 10.4 ± 1.2*
10 % 6.5 ± 1.5 11.6 ± 0.9
0% NA 8.3 ± 1.0*
50%* 5 ± 0 11.6 ± 0.4*
.
ed, FucT dko and C57BL/6 (LN/PP/Sp+/+) mice received cell mixtures of
FucT dko recipients of syngeneic BMT from FucT dko donors severed as
MT, some FucT dko mice were also treated i.p. with monoclonal anti-
munoglobulin) at the dose and schedule described in the Materials and
oughweek 5 for the development of clinical GVHD. In addition, intestinal
analyzed for evidence of target tissue injury. Data were combined from 2
eneic group.
Table 2. Donor T cell numbers in the BM and liver 7 days after BMT
bone marrow (x106) liver cells (x106)
CD3+ H2kd+ CD3+H2Kd+ CD3+ H2kd+ CD3+H2Kd+
Syn 0.40 ± 0.07 N/A N/A 0.59 ± 0.12 N/A N/A
Allo Co 0.47 ± 0.01 3.45 ± 0.52 0.41 ± 0.07 0.23 ± 0.51 0.99 ± 0.68 1.59 ± 0.39
LN/PP/Sp+/+ 1.05 ± 0.28 1.92 ± 0.97 0.41 ± 0.19 1.07 ± 0.31 0.90 ± 0.44 0.78 ± 0.42
LN/PP/Sp-/- 1.12 ± 0.12*,‡ 8.85 ± 1.5†,‡ 1.17 ± 0.18†,‡ 3.57 ± 0.68*,†,‡ 4.75 ± 1.10†,‡ 3.10 ± 0.54†,‡
Lethally irradiated, LN/PP/Sp2/2, LN/PP/Sp+/+, and wild-type C57BL/6 recipients received BMT as in Figure 2. Seven days after BMT, single cell
suspensions were prepared from the bone marrow cavity or liver tissue, and cells from individual mice were labeled and analyzed by flow cytometry.
Increased numbers of donor T cells are present in the BM and liver of LN/PP/Sp2/2 mice compared to allogeneic controls. Data are presented as
mean 6 SEM and represent 1 of 3 similar experiments.
*p< 0.05 compared to syn; †p< 0.05 compared to Allo Co; ‡p< 0.05 compared to LN/PP/Sp +/+
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were used as BMT donors to take advantage of more
robust T cell activation observed in this model. The
total number (Table 3) and percentage (Figure 5a) of
donor, CD31 cells present in the BM cavity of LN/
PP/Sp2/2 allo-BMT recipients was 10-fold higher
than that observed in allogeneic LN/PP/Sp1/1 litter-
mate controls. As expected, these cells expressed
CFDA-SE, and flow cytometric analysis revealed that
they had undergone a significant number of cell divi-
sions (Figure 5a). By contrast very few CFDA-SE ex-
pressing donor T cells were present in the BM of
LN/PP/Sp1/1 controls. Moreover, the number of
donor T cells in the BM of LN/PP/Sp2/2 allo-
BMT recipients coexpressing the activation markerLiver GVHD
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Figure 4. Early infiltration of donor T cells into the livers of LN/PP/
Sp2/2 mice correlates with the severity of hepatic GVHD on day 7 af-
ter BMT. Lethally irradiated LN/PP/Sp2/2and LN/PP/Sp1/1 and wild-
type C57BL/6 recipients received BMT as in Figure 2. Liver tissue was
collected on day 7, and the severity of GVHD was determined as de-
scribed in the Materials and Methods section. Data are presented as
mean 6 SEM, and were combined from 2 similar experiments. n 5 6
to 10 per group. *P\.05, allo C57BL/6 and LN/PP/Sp1/1 versus syn;
#P\.01, LN/PP/Sp2/2 versus all groups. syn ; allo C57BL/6 ; LN/
PP/Sp1/1 ; LN/PP/Sp2/2 .CD69 was also significantly increased (Table 3).
When we specifically evaluated donor CD41 and
CD81 T cell subsets in the BM of LN/PP/Sp2/2
allo-BMT recipients, we found that in each case, donor
T cells expressed activation markers and produced
both IFNg and TNFa upon restimulation (Figure 6a
and b). This modest increase in cytokine production
was confirmed in additional experiments showing
that mRNA expression of IFNg and TNFa was in-
creased compared to cells collected from syngeneic
controls (Figure 6c). Importantly, mRNA expression
of perforin was also increased (1.43-fold compared to
syngeneic), and these T cells also possessed cytolytic
activity against allogeneic tumor targets in vitro
(Figure 6c).
Although a greater number of donor T cells were
also found in the liver of LN/PP/Sp2/2 mice on
day 3, these cells were not significantly activated or di-
viding (Figure 5b and Table 3). Of note, we found that
the absolute numbers of BM cells from naı¨ve aly/aly,
aly/1 and C57BL/6 mice are comparable suggesting
that the increased numbers of donor T cells present
in LN/PP/Sp2/2 allo-BMT recipients was not be-
cause of an intrinsic alteration in cellular migration
to the BM cavity in these mice (data not shown).EVALUATION OF GVL EFFECTS IN LN/PP/
Sp2/2 MICE FOLLOWING ALLO-BMT
We next determined whether the activation of do-
nor T cells observed in the in the BM cavity of LN/PP/
Sp2/2mice early after BMT and prior to the develop-
ment of clinical and target organ GVHD was also as-
sociated with preservation of GVL effects. In these
experiments, irradiated LN/PP/Sp2/2 and LN/PP/
Sp1/1mice received allo-BMT from B10.BR donors
as in Figure 3, and LN/PP/Sp2/2 recipients of synge-
neic BMT served as controls. In separate experiments,
increasing numbers (1000, 2000, and 5000) of host-
type, (H-2b) MBL-2 tumor cells were added to the
BM inoculum in some allogeneic and syngeneic
groups. BMT recipients were subsequently monitored
for survival, and cause of death was recorded asGVHD
Table 3. Donor T cell expansion and activation in the bone marrow and liver 3 days after BMT
Bone Marrow (cells x 105) Liver (cells x 105)
CD3+CFSE+ CD3+CFSE+CD69+ CD3+CFSE+ CD3+CFSE+CD69+
Syn 0.39 ± 0.17 0.26 ± 0.07 0.14 ± 0.15 0.10 ± 0.22
LN/PP/Sp+/+ 0.07 ± 0.00 0.04 ± 0.00 0.43 ± 0.08 0.27 ± 0.07
LN/PP/Sp-/- 0.87 ± 0.00# 0.72 ± 0.00# 0.75 ± 0.01* 0.29 ± 0.08
BMT indicates bone marrow transplantation. T cells (10  106) from B10.BR donors were stained with vibrant CFDA SE and infused into lethally irra-
diated, LN/PP/Sp2/2 or LN/PP/Sp+/+ recipients as described in Figure 5. Three days after transfer, single cell suspensions were prepared from the bone
marrow cavity (A) or liver tissue (B) and cells from mice in each group were pooled (BM) or processed individually (liver) and subsequently counted,
labeled, and analyzed by flow cytometry. Increased numbers of activated and dividing donor T cells are present in the BM of LN/PP/SP2/2 mice com-
pared to allogeneic, LN/PP/Sp+/+ littermate controls. Data are presented as mean 6 SEM, and represent 1 of 3 similar experiments, n 5 4 mice per
group per experiment.
*P < .05, #P 5 .06.
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section. Recipients of syngeneic BMT that did not
receive tumor cells all survived, whereas all LN/PP/
Sp1/1 recipients of allogeneic BMT died of GVHD
prior to day 20 regardless of whether MBL-2 cells
were added at day 0 (data not shown). As expected, syn-
geneic BMT recipients uniformly died of disseminated
MBL-2 tumor cell infiltration regardless of tumor
dose. Although the majority of LN/PP/Sp2/2 allo-
BMT recipients effectively rejected their tumor and
survived at the lowest tumor dose, this effect was lost
when we increased the tumor burden at the time ofFigure 5. Division of donor T cells in bone marrow cavity and liver 3 days fo
Vibrant CFDA SE and infused into lethally irradiated, LN/PP/Sp2/2 or LN/P
Three days after transfer, single cell suspensions were prepared from the bon
and analyzed by flow cytometry. Data are presented as percent of total cells coBMT by 2- and 5-fold in subsequent experiments
(Figure 7a-c).DISCUSSION
GVHD remains the major complication of allo-
BMT. Unfortunately, GVHD is tightly linked, both
clinically and biologically, to potent and desirable
GVL effects. GVHD and GVL responses are depen-
dent upon the activation of donor T cells by APCs
[30,31], but the precise location of these interactionsllowing BMT. T cells (10  106) from B10.BR donors were stained with
P/Sp1/1 recipients as described in the Materials and Methods section.
e marrow cavity (A) or liver tissue (B), and cells were pooled, labeled,
llected from each tissue and are shown from 1 of 3 similar experiments.
Figure 6. Donor CD41 and CD81 T cells present in the bone marrow of LN/PP/Sp2/2 BMT recipients are activated, produce cytokines, and are
capable of killing allogeneic targets in vitro. T cells (10  106) from B10.BR donors were infused into lethally irradiated, LN/PP/Sp2/2 recipients as
described in the Materials and Methods section. Three to 5 days after transfer, single cell suspensions were prepared from the bone marrow cavity
and cells were pooled, labeled, and analyzed by flow cytometry for cell surface (A), intracytoplasmic cytokine production (B), mRNA expression (C)
and cytolytic function against allogeneic (solid square) or syngeneic (solid circle) targets (D). Data shown are representative from 1 of 3 (A, B, D) or
2 (C) similar experiments (n 5 3 to 4 animals per experiment).
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SLO contribute to, but are not required for the
development of GVHD using MHC disparate mouse
strains following MA conditioning. In this context,
we identified the BM as a possible alternative,
nonlymphoid organ where T cell activation can occur
early after BMT. However, our data show that the
allo-stimulatory capacity of the BM cavity is less
efficient than that of traditional SLOs; GVHD,
although clearly present, is less severe, and associated
GVL responses, although present, could be overcome
when the tumor burden was increased.
Several groups have studied the role of various
SLOs in the generation of allo-immune responsesfollowing BMT, and published data on this topic are
conflicting. Murai and colleagues [1] were the first to
demonstrate that a role for PPs in the development
of GVHD; disrupting the recruitment of donor T cells
into PP using several strategies effectively prevented
GVHD induction following NMA conditioning.
This model is characterized by the adoptive transfer
of donor T cells (without BM rescue) and the ultimate
reliance on a ‘‘graft-versus-host hematopoietic cell’’ re-
sponse, wherein allo-BMT recipients die of BM apla-
sia. By contrast, subsequent data by Welniak et al. [3]
showed that PPs are not required forGVHD following
MA conditioning. These differences might be ex-
plained in part by the effects that dose intense regimens
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Figure 7. Evaluation of GVL responses in LN/PP/Sp2/2 following allo-BMT. Lethally irradiated, LN/PP/Sp2/2 and LN/PP/Sp1/1 and wild-type
C57BL/6 recipients received BMT from syngeneic or allogeneic, B10.BR donors as in Figure 3. On day 0, either 1000 (A) or 2000 (B) or 5000 (C)
MBL-2 cells were added to the donor stem cell inoculum. Survival was monitored daily and the cause of each death after BMTwas determined by post-
mortem examination and ascribed to either GVHD or leukemia as described in the Materials and Methods section. In each case, data are combined from
2 different experiments (n 5 8 to 16 per group).
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inflammatory milieu created by MA conditioning is
known to have a significant impact on the trafficking
of alloreactive T cells into target tissues [3,32,33].
PPs have also been found to contribute to the hom-
ing and priming of T cell effectors responsible for in-
testinal aGVHD in some models [2,34]. In the early
phase of allo-BMT, circulating naı¨ve donor T cells
rapidly enter into the host SLO by using homing mol-
ecules such as L-selectin, a4b7, MAdCAM-1, and the
chemokine receptor CCR7. In particular, a4b7 has
been shown to be an important intestinal homing re-
ceptor for both the naı¨ve and effector/memory T cells.
During GVHD, donor T cells gradually upregulate
the adhesion molecule a4b7 as they differentiate into
effector cells [26], and subsequently interact with
MAdCAM-1-bearing high endothelial venules in PPs
patches, mesenteric LNs, and lamina propria venules
in the intestine [1,26,34]. Preventive measures
targeting these molecules inhibit the development of
antihost CTL and ameliorate GVHD [1,26,34,35].
Experiments using in vivo fluorescein imaging to
track cell migration have also supported a role for
SLO in the activation of donor T cells following allo-
geneic BMT and have revealed increased numbers of
T cells in the spleen and peripheral LN, such as PP
and mesenteric LN (mLNs) at early time points after
BMT and prior to infiltration into the small and large
bowel [2]. These findings were recently expanded
upon by work showing that strategies blocking T cell
trafficking to all SLO completely abrogates biolumi-
nescent signals and cellular infiltration into the intesti-
nal track early after BMT and results in long-term
survival [36]. Our results confirm and extend these
findings; LN/PP/Sp2/2 aly/aly allo-BMT recipients
all survive, but closer examination of surviving mice
at later time points after BMT clearly show that they
ultimately develop significant clinical and histopatho-
logic evidence for GVHD, similar to finding reported
by Anderson and colleagues [37]. When compared to
LN/PP/Sp1/1 controls, hepatic GVHD was morerobust in LN/PP/Sp2/2 allo-BMT recipients,
whereas GI GVHD was less severe. This observation
supports a particularly key role for PPs and mesenteric
lymph nodes in the recruitment of donor cells and the
development of allo-immune inflammation in intesti-
nal track as suggested by others [2,34].
Results included herein also suggest that the bone
marrow space may serve as an alternative, albeit less ef-
ficient site of donor T cell activation following MA
conditioning. The BM cavity displays structural and
functional features of a SLO; it contains follicle-like
structures similar to LNs or spleen, can initiate
primary T cell responses, and represents a major
part of the lymphocyte recirculation network
[38,39]. The frequency of lymphoid follicles in BM
can increase during infection, inflammation, and
autoimmunity [38,40]. In this context, the BM seems
to be unique among lymphoid organs in performing
primary and secondary immune functions, hemato-
and lymphopoiesis, and systemic immune control of
blood-borne antigen. We found that donor T cell
(CD31) expansion, activation (CD691) and prolifera-
tion (CFDA-SE) was significantly higher in the BM of
aly/aly LN/PP/Sp2/2 recipients 3 days after BMT
compared to allogeneic LN/PP/Sp1/1 littermate
and wild-type C57BL/6 controls. Following activa-
tion, increased numbers of donor T cells were
observed in the liver by day 7 and correlated with sig-
nificant hepatic GVHD at that time. Our findings are
in accord with recent studies showing that antigen pre-
sentation to T cells could be mediated by DCs in the
BM space of aly/aly (Sp1) mice.
Recently, BM-resident DCs have been shown to
be critical for maintenance of recirculating B cells
and capable of T cell activation [38,41] Following
the adoptive transfer of CD41 and CD81 T cells,
the formation of multicellular clusters of T cells
and BM-resident DCs was associated with the subse-
quent activation and proliferation of the transferred
T lymphocytes. T cell activation was not tolerogenic,
and resulted in generation of CTL activity in situ
Biol Blood Marrow Transplant 16:598-611, 2010 609Secondary Lymphoid Organs and GVHDwithin the BM, protective antitumor immunity, and
immunologic memory [38]. Moreover, work by Beil-
hack and colleagues [36] showed that bioluminescent
signals in splenectomized mice receiving antibodies
to CD62L and MAdCAM-1 projected predomi-
nantly to the BM compartments in mice receiving
allo-BMT.
In our final set of experiments, we determined
whether the graft-versus-host activity that resulted in
significant systemic and target tissue GVHD was ro-
bust enough to generate protective GVL effects. Al-
though LN/PP/Sp2/2 allogeneic BMT recipients
were capable of generating CTL activity to allogeneic
tumor targets in vitro, GVL responses in vivo were
overcomewhen the tumor burdenwas increased, albeit
to a level 4-fold less than that effectively rejected in
other BMT strain combinations [22]. These findings
diverge from those of reported by Feuerer and col-
leagues [39]. One explanation for these differences is
that aly/aly mice were splenectomized and lethally
irradiated prior to the infusion of tumor cells in our
experiments, whereas nonirradiated mice with a full
complement of immune cells were used in previous
studies. Indeed, we found that nonirradiated, naı¨ve
aly/aly mice were able to reject and thereby survive
an allogeneic tumor challenge (data not shown). It is
also possible that the generation of significant CTL re-
sponses is slower in the BM, and as such, challenging
mice at later time points after BMT could reveal the
presence of more robust antitumor activity. Results
more consistent with ours were observed in a report
examining immunologic responses to lymphocytic
choriomeningitis virus (LCMV) in unirradiated aly/
aly (Sp1). In these studies, CTL induction was found
to be present early after infection, but LCMV-specific
CTLwere rapidly exhausted and remained suboptimal
even when aly/aly mice were reconstituted with wild-
type BM [10,42].
Although the BM may function as an alternative,
nonlymphoid site for T cell activation and the develop-
ment of GVHD in animals devoid of traditional SLOs,
other explanations for this surprising finding were con-
sidered. Prior to BMT experiments, we found that the
ability of splenic and BM-derived DCs, from aly/aly
mice to stimulate allogeneic T cell proliferation,
IFNg secretion, and CTL generation was comparable
to naı¨ve, aly/1 littermate, and wild-type C57BL/6
mice, thus ruling out enhanced allo-stimulatory capac-
ity as a cause for persistent GVHD in splenectomized,
aly/alyBMT recipients.Work done byMatsumoto and
colleagues [43] found that defective lymphoid organ
development in aly/aly mice is partially restored by
the generation of chimeras with normal donors early
in development, suggesting that agenesis of LN and
PP in aly/alymice is primarily dependent upon stromal,
rather than hematopoietic elements. This is in contrast
to that observed in LTa2/2 mice, where similar chi-mera experiments resulted in complete restoration of
SLO architecture in LTa2/2 mice. Although partial
restoration of PPs was noted in some recipients of syn-
geneic BMT, similar observationswere not observed in
allo-BMT recipients (data not shown). Similarly, it is
possible that the presence of other nontraditional,
SLO-like nasal-associated lymphoid tissue could con-
tribute toT cell activation, but these siteswere not fully
evaluated in this study. Finally, although we and others
have found that normal DC function, particularly with
respect to stimulating allo-antigen responses, is pre-
served in aly/aly mice [5,6,9,10], recent data have
demonstrated that the capacity for DCs to expand
CD251 CD41 regulatory T cells in vitro, is
impaired, and contributes to decreased numbers of
regulatory T cells in the periphery of aly/aly mice
[44]. It is therefore possible that this effect contributes,
at least in part, to the persistence of significant, albeit
attenuated GVH responses seen in splenectomized
aly/aly allo-BMT recipients.
Collectively, our data generated using mice ana-
tomically or functionally devoid of SLOs challenge
the paradigm that these structures are required for
the induction of GVH responses. Because our studies
were conducted with fully MHC disparate mouse
strains, our results do not discount that blocking en-
trance into SLO could be a clinically viable option to
reduce GVHD in the context of less severe MHC dis-
parity. Rather, we believe these findings enhance our
understanding of where T cell-APC interactions occur
during the development of GVHD, and anticipate that
insights derived from this work will ultimately improve
current clinical strategies to optimize the impact graft-
versus-host responses have on our patients receiving
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